



EOS imaging obtains FDA Approval for hipEOS, the First 3D Stereoradiographic Planning Software for Hip Arthroplasty

EOS will launch hipEOS in the US at the 2015 AAOS Annual Meeting in March

Paris, Dec. 15, 2014 – EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, announced today that the U.S. Food and Drug Administration has approved hipEOS, a 3D hip arthroplasty planning software based on EOS stereo-radiographic 2D/3D imaging.

hipEOS is the first offering of a software portfolio associated with the EOS imaging system. Developed by OneFit medical, an EOS imaging group company, the software enables surgeons to perform, using EOS unique stereo-radiographic 2D/3D low dose images, pre-surgical planning including hip implant selection and virtual positioning in functional, weight-bearing 3D. The software takes full advantage of the bias-free, real size 3D patient anatomical information obtained from the EOS exam to help physicians define implant size and visualize pre-operatively the restoration expected from a total hip arthroplasty prior to surgery. hipEOS received a CE Mark in March 2014.

Hip arthroplasty is the first procedure that will be addressed with planning software utilizing the advantages of EOS unique imaging. The Company intends to expand the suite of offerings to include additional orthopedic surgery planning software.

The hipEOS software will be officially launched in the U.S. at the American Academy of Orthopedic Surgeons Annual Meeting, March 24-28 in Las Vegas.

Marie Meynadier, CEO of EOS imaging, said, *“hipEOS is the first step of our strategy to fully utilize EOS’ unique stereo-radiographic 2D/3D patient data in software tools that will help surgeons plan and execute precise surgical and non surgical treatments. We are very happy to have been granted market approval in the U.S. and to extend this offering, which has received a very positive feedback at the French SOFCOT launch in November, to our U.S. users and future users.”*

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

EOS imaging has been chosen to be included in the new EnterNext® PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 34 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.



EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI



Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Sophie Boulila / Pierre Laurent

Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Melanie Sollid-Penton

Ph: 646-536-7023

msollid@theruthgroup.com